Freeze-dried multi-dose kits for the fast preparation of 177Lu-Tyr3-octreotide and 177Lu-PSMA(inhibitor) under GMP conditions

German Multicenter Study Investigating¹⁷⁷Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

Kambiz Rahbar, Hojjat Ahmadzadehfar, Clemens Kratochwil et al. · Journal of Nuclear Medicine · 2016 · 832 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients

Dik J. Kwekkeboom, Willem H. Bakker, P.P.M. Kooij et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2001 · 471 citations

Medicine, Endocrinology, Nuclear Medicine +3

Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

Jolanta Kunikowska, Leszek Królicki, Alicja Hubalewska–Dydejczyk et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2011 · 237 citations · Full text

Medicine, Nuclear Medicine, Oncology +15

[¹⁷⁷Lu-DOTA]⁰-D-Phe¹-Tyr³-Octreotide (¹⁷⁷Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study

Richard P. Baum, Andreas Kluge, Harshad Kulkarni et al. · Theranostics · 2016 · 101 citations · Full text

Medicine, Oncology, Pharmacology +16

Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with <sup>177</sup>Lu and Conjugated to Peptides

Guillermina Ferro‐Flores, Blanca Ocampo‐García, Clara Santos‐Cuevas et al. · Current Radiopharmaceuticals · 2015 · 31 citations

Pharmacy, Nuclear Medicine, Pharmaceutics +17